Palisade Bio, Inc. (PALI) stock

PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30

$1.12−0.02 (-1.75%)

Close on Nov 13, 2026Market cap $195.18MP/E –Yield –

Palisade Bio statistics

70 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $195.18M; $272.32M
Enterprise Value: $81.57M; $146.23M
PS Ratio: 390.37; 3.66
PB Ratio: 1.74; 2.00
P/TBV Ratio: 1.74; 2.22

Enterprise valuationIndustry

EV / Sales: 163.14; 2.57

Share statisticsIndustry

Shares Outstanding: 174M; 58M
Shares Change (QoQ): 0.49%; 0.50%
Float: 166M; 49M
Shares Held by Insiders: 4.66%; 11.7%
Shares Held by Institutions: 99.5%; 56.4%

Short sellingIndustry

Short Interest: 29M; –
Short Interest Change: -7.74%; -0.80%
Short % of Float: 17.6%; 9.01%
Short % of Shares Outstanding: 16.8%; 6.30%
Days to Cover: 7.76; 5.15

Stock price statisticsIndustry

52-Week High: $2.85; –
52-Week Low: $1.08; –
20-Day Moving Average: $1.22; –
50-Day Moving Average: $1.48; –
200-Day Moving Average: $1.82; –
Average True Range (14): $0.10; –
Price Change (1 Week): -0.88%; -1.15%
Price Change (1 Month): -27.3%; -4.87%
Price Change (3 Months): -47.9%; -21.0%
Price Change (6 Months): -38.8%; -20.6%
Price Change (YTD): -52.3%; -23.6%
Price Change (1 Year): -45.1%; -22.4%
Price Change (3 Years): -85.6%; -29.5%
Price Change (5 Years): -99.9%; -77.9%
Price Change (10 Years): -100.0%; -65.4%
Average Volume (10 Days): 4M; –
Average Volume (20 Days): 4M; –
Average Volume (90 Days): 3M; –
Relative Volume: 0.51; 0.70
Relative Strength Index (14): 37.0; 43.4
Volatility (1 Year): 89.0%; 80.1%
Beta (5 Years): 0.97; 1.07

MarginsIndustry

Operating Margin: -9625.4%; -38.7%
Profit Margin: -8739.2%; -31.6%
EBITDA Margin: -9625.4%; -27.7%

Returns on capitalIndustry

Return on Equity (ROE): -75.6%; -49.9%
Return on Assets (ROA): -69.6%; -40.6%
Return on Capital Employed (ROCE): -42.7%; -37.9%

Financial positionIndustry

Current Ratio: 20.16; 3.30
Quick Ratio: 19.50; 2.39
Interest Coverage: -16042.30; -6.35

EfficiencyIndustry

Asset Turnover: 0.01; 0.40
Revenue Per Employee: $5; $429.29K
Profits Per Employee: -$437; -$689.41K
Employee Count: 100,000; 74
WACC: 9.93%; 10.2%

Income statement (TTM)Industry

Revenue: $500.00K; $66.37M
Operating Income: -$48.13M; -$21.37M
Net Income: -$43.70M; -$22.35M
EBITDA: -$48.13M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $113.61M; $68.68M
Net Cash (Debt): $113.61M; $17.76M
Net Cash Per Share: $0.65; $0.80
Equity (Book Value): $112.44M; $53.89M
Book Value Per Share: $0.65; $1.50
Tangible Book Value: $112.44M; $27.13M
Working Capital: $111.65M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$26.40M; -$12.38M

Dividends and yieldsIndustry

Earnings Yield: -22.4%; -21.8%
Buyback Yield: -67.5%; -0.76%
Shareholder Yield: -67.5%; 0.00%

Taxes and interestIndustry

Interest Expense: $3.00K; $2.90M

Scores and fair valueIndustry

Altman Z-Score: 18.98; 0.23
Piotroski F-Score: 4; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	PALI	S&P 500	Difference	PALI per year	S&P 500 per year
1 month	-23.5%	-3.0%	−20.5 pts
3 months	-47.9%	-2.8%	−45.1 pts
Year to date	-52.3%	+11.5%	−63.8 pts
1 year	-40.1%	+13.5%	−53.6 pts
3 years	-85.9%	+77.7%	−163.6 pts	-48.0%	+21.1%
5 years	-99.9%	+72.6%	−172.6 pts	-77.6%	+11.5%
10 years	-100.0%	+308.2%	−408.2 pts	-71.6%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

29M PALI shares were sold short on Oct 30, 2026, down 7.7% from the previous report, or 17.63% of the shares available to trade. At recent volumes it would take 7.8 days to buy them back. Over the last 20 sessions, 29.0% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	29,290,111	-7.7%	3,775,010	7.8
Oct 15, 2026	31,746,628	+2.4%	1,981,561	16.0
Sep 30, 2026	31,015,282	+2.5%	5,116,812	6.1
Sep 15, 2026	30,267,286	-2.1%	2,200,098	13.8
Aug 31, 2026	30,902,111	-7.5%	1,616,674	19.1
Aug 14, 2026	33,391,318	-0.9%	1,515,332	22.0
Jul 31, 2026	33,699,995	-9.0%	2,311,213	14.6
Jul 15, 2026	37,022,896	+15.2%	3,711,036	10.0
Jun 30, 2026	32,129,387	+1.9%	6,010,460	5.3
Jun 15, 2026	31,519,540	+2.3%	2,649,988	11.9
May 29, 2026	30,806,978	+14.4%	2,856,005	10.8
May 15, 2026	26,920,839	+3.0%	2,587,250	10.4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Palisade Bio's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Apr 8, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PALI.

Compare: PALI vs CRDF · PALI vs YARW · PALI vs IMA · PALI vs CMPX · PALI vs SRRK

Operating margin-9625.4% · median -8949.6%

Net margin-8739.2% · median -8097.7%

Company	Revenue	Growth
SRRK	$570.00K	–
CRDF	$559.00K	+11.6%
PALI	$500.00K	–
YARW	$476.00K	-2.1%
IMA	–	–
CMPX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 100,000
Held by institutions: 99.5%
Auditor: Baker Tilly US, LLP
SEC CIK: 1357459

Advertisement
300 × 250

See a number that looks wrong?